Global X HealthTech ETF

FAMAR Group Signs Contract Manufacturing Agreement with GE HealthCare to Expand Iodine Contrast Agent Capacity

Oscar Health CFO Richard Scott Blackley Sells 100k Shares for $2.32M

Bank of America Lowers Intuitive Surgical Target Price to $520, Maintains Buy Rating

Dexcom Announces Launch of Dexcom Flex Continuous Glucose Monitoring System in Germany

GEHC Receives 'Hold' Consensus from 17 Brokers, Executives Buy Shares to Show Confidence

Barclay's Analyst Matt Miksic Maintains Sell Rating on Dexcom with $64 Target

Dexcom Investor Day: Focus on G8 New Product, Doubling US CGM Coverage, and International Expansion Strategy

Wall Street Zen Upgrades Intuitive Surgical to Buy; Earnings and Revenue Beat Expectations

Dexcom Announces 2030 Targets: 10% Revenue Growth and $10B Buyback

RBC Capital Analyst Maintains Hold Rating on Royal Philips with a Price Target of €25

Macquarie and Citibank Reiterate Buy Rating on ResMed CHESS Depositary Interests

IQVIA Reports Strong Q1 Earnings and Raises Full-Year Guidance

GE HealthCare to Showcase AI-driven Radiotherapy Tools at ESTRO 2026

ViCentra Launches Its New Kaleido Insulin Delivery Patch Pump System Commercially

GE HealthCare Director Receives Restricted Stock Units and Buys Stocks

Brummer Multi Strategy AB Upgrades IQVIA Holdings Inc. Shares

ASR Vermogensbeheer N.V. Significantly Reduces Holdings in IQVIA Holdings Inc.

Oscar Health's stock target price raised to $20.09

Citigroup analyst maintains buy rating on ResMed

IQVIA Approves $2 Billion Stock Repurchase Plan

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Wellgistics Health

Huachen AI Parking Management Tech

GeoVax Labs

Sunshine Biopharma

AIM ImmunoTech

Virax Biolabs

NextNRG

GCT Semiconductor

DOCS

HEAL

Doximity, Inc. reported Q4 and full-year fiscal 2026 results with revenue growth but declining net income. The company faces challenges with softer fiscal 2027 guidance due to increased AI spending. A new integration with Aledade's platform aims to enhance its AI tools' role in clinical workflows. Analysts express caution over revenue growth and margin pressures, while Doximity's long-term projections suggest significant upside potential. Investors are advised to consider various perspectives before making decisions.

Simplywall

Doximity

iShares Expanded Tech Software Sector ETF

First Trust Nasdaq Lux Digital Health Solutions ETF

SPDR S&P Software

Doximity (DOCS) Is Down 27.0% After Softer 2027 Outlook And Higher AI Spend - What's Changed

This week, notable analyst calls included Dell downgraded to Neutral by UBS due to AI server demand being priced in, while J&J was upgraded to Outperform by Leerink Partners on growth prospects from new products. Akamai was upgraded to Buy by BofA, citing its shift to AI infrastructure. AMD was downgraded by Daiwa as recent price rises may moderate. Doximity and Goodyear were also downgraded due to disappointing guidance and raw material pricing issues, respectively.

- Wall Street’s major market averages declined on Friday due to falling tech stocks and rising U.S. Treasury yields after the U.S.-China summit.  
- Analysts issued several upgrades and downgrades, with Dell being downgraded by UBS, which noted that AI server demand is "largely priced in."  
- The overall market sentiment reflected cautious trading as investors reacted to economic signals and analyst recommendations.

Johnson & Johnson

Akamai Tech

GraniteShares 2x Long DELL Daily ETF

First Trust Nasdaq Food & Semicon

Invesco PHLX Semiconductor ETF

SPDR S&P Semicon

iShares Semiconductor ETF

VanEck Semiconductor ETF

SPDR S&P Health Equip

iShares US Medical Devices

GraniteShares 2x Long AMD Daily ETF

VG Health

Direxion Semicon Bull 3X

iShares Global Healthcare

iShares US Pharma

Invesco Semiconductors ETF

Health Care Select Sector SPDR

Direxion Daily AMD Bull 2X Shares

Dell Tech

UBS Group AG

Notable analyst calls this week: Dell, J&J and AMD stocks among top picks

LGHT

Barclays has downgraded Doximity (NYSE:DOCS) from a 'strong-buy' to a 'hold' rating. Other analysts have also reduced their price targets, with Mizuho lowering it to $26, Goldman Sachs to $24, and BMO to $20. Doximity's stock currently has a consensus rating of 'Hold' and a target price of $30.62. The company has a market cap of $3.50 billion and recently approved a $500 million stock buyback program.

Market Beat

Langar Global HealthTech ETF

Barclays

Mizuho Financial

Mizuho Financial Group, Inc.

Goldman Sachs

Bank of Montreal

Atlantic Union Bankshares

GS Hldg R

ATLANTIC UNION BANKSHARES CORP 6.875% DEP SH RP 1/400 NON CU PR PF SR A

Atlantic Union Bankshares Corporation

Barclays Downgrades Doximity (NYSE:DOCS) to Hold

TDOC

EDOC

FDHT

UBS analyst Kevin Caliendo has maintained a Hold rating on Teladoc (TDOC) with a price target of $6.00. Caliendo, a 4-star analyst, has an average return of 3.5% and a 53.71% success rate. Previously, Citi's Daniel Grosslight also issued a Hold rating, while Canaccord Genuity maintained a Buy rating on April 30.

Tip Ranks

Teladoc

Global X Telemedicine & Digital Health ETF

Fidelity Digital Health ETF

Dentsply Sirona

Cencora

Henry Schein

Citigroup

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Teladoc (TDOC) Gets a Hold from UBS

Doximity, Inc. (NYSE:DOCS) has received a consensus recommendation of 'Moderate Buy' from 24 analysts. Thirteen rated it as hold, nine as buy, and two as strong buy. The average 12-month target price is $30.62. Recent analyst reports show varied price targets, with BMO Capital Markets lowering theirs to $20 and Piper Sandler raising it to $42. Insider transactions revealed significant stock sales, and institutional investors hold 87.19% of shares.

Piper Sandler Cos

Morgan Stanley

Evercore

MORGAN STANLEY DEP SHS EA REP 1/1000 SHS NON CUM PFD O

MORGAN STANLEY DEP SHS REPSTG 1/1000TH PFD SER Q

MORGAN STANLEY DEP SHS REPS 1/1000 7.125% PFD E

MORGAN STANLEY NON-CUM DEP SH REP 1/1000 PFD SER I

MORGAN STANLEY 4.875 DEP SHS REP 1/1000 NCUM PFD SR L

MORGAN STANLEY 6.5%DEP SHS REPSTG 1/1000 NON CUM SER P

MORGAN STANLEY DEP SHS REPS 1/1000 PFD SER 'A'

MORGAN STANLEY DEP SHS REPR 1/1000TH INT PFD SER 'F' FX

MORGAN STANLEY DEP SHS REP 1/1000 NON-CUM PFD STK SER K

Doximity, Inc. (NYSE:DOCS) Given Average Recommendation of "Moderate Buy" by Analysts

JPMorgan Chase & Co. has lowered its price target for Doximity (NYSE:DOCS) from $33.00 to $28.00, maintaining a "neutral" rating. This suggests a potential upside of 60.38% from the previous close. Other brokerages have also adjusted their targets, with Robert W. Baird setting a target of $18.00, BMO Capital Markets at $20.00, and Bank of America at $47.00. Doximity's stock traded down to $17.46, with a market cap of $3.22 billion. Insiders have sold shares recently, indicating potential concerns about the stock's valuation.

JPMorgan Chase

Defiance Daily Target 2X Long JPM ETF

JPMorgan Chase & Co. Lowers Doximity (NYSE:DOCS) Price Target to $28.00

AVAH

BIIB

Healthcare stocks declined on Thursday, with the NYSE Healthcare Index down 0.1%. Biogen shares fell nearly 6% after a failed Alzheimer's trial. Prestige Consumer Healthcare reported disappointing Q4 results and lowered 2026 guidance, leading to an 8% drop in shares. Doximity's shares dropped over 24% after issuing weak guidance, despite long-term growth potential. In contrast, Aveanna Healthcare shares rose 11% following strong Q1 earnings and an increased revenue forecast for 2026.

Fidelity

Aveanna Healthcare

Biogen

Prestige Brands

SPDR S&P Biotech

iShares US Healthcare Providers

iShares US Healthcare

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

Direxion S&P Biotech Bull 3X

iShares Genomics Immunology and Healthcare ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

SPDR S&P Health

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Proshares Ultra Nasdaq Biotech

Sector Update: Healthcare Stocks Softer Thursday Afternoon

Doximity (DOCS) shares dropped 24% following mixed Q4 results and a weaker FY2027 outlook, prompting analysts to downgrade ratings. Wells Fargo's Stan Berenshteyn lowered the rating to Hold and cut the price target to $18, citing risks in AI competition and rising costs. BTIG's David Larsen also downgraded the stock, highlighting a challenging macro environment and weak pharma demand. Despite the downturn, analysts maintain a Moderate Buy consensus on DOCS, with an average price target of $28.12, suggesting a potential upside of 56.91%.

Wells Fargo

Veeva Systems -CL

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

Why Is Doximity Stock (DOCS) Falling Today, 5/14/26?

Doximity shares fell 24% following disappointing Q4 results, prompting analysts to downgrade ratings and lower price targets. KeyBanc Capital Markets downgraded the stock from Overweight to Sector Weight, citing weak fiscal 2027 growth guidance of 3%-5% and challenges in the pharma ad market. Needham maintained a Buy rating but reduced the price target from $55 to $27, noting revenue growth of 5.1% year-on-year but concerns over decelerating growth. Doximity's stock was trading at $17.70 at the time of the report.

Doximity Sinks 24% As AI Push Fails To Ease Growth Fears

Doximity (DOCS) fell approximately 25% to an all-time low following disappointing Q4 fiscal 2026 results, leading to a downgrade by KeyBanc Capital Markets. The company's guidance did not meet Wall Street expectations, marking the lowest stock price since its IPO in 2021.

Global X HealthTech ETF(HEAL.US)